贝瑞基因(000710) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was CNY 304,909,782.99, a decrease of 18.26% compared to the same period last year[5] - The net profit attributable to shareholders was CNY -39,849,162.34, representing a decline of 1,746.17% year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY -32,819,121.14, down 1,622.53% from the previous year[5] - The company reported a net loss of CNY -133,132,588.87, a decline of 866.25% year-on-year, primarily due to decreased operating income and losses from joint ventures[9] - Net loss attributable to shareholders for Q3 2023 was CNY 134,956,919.35, compared to a loss of CNY 16,194,159.31 in Q3 2022, representing an increase in loss of 733.5%[18] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,090,505,398.03, a decrease of 3.45% from the end of the previous year[5] - Total assets as of Q3 2023 amounted to CNY 3,090,505,398.03, a decrease from CNY 3,200,862,871.74 at the end of Q3 2022[16] - Total liabilities as of Q3 2023 were CNY 890,967,458.56, compared to CNY 871,535,028.84 in Q3 2022, reflecting an increase of 2.5%[16] - The company's total equity decreased to CNY 2,199,537,939.47 from CNY 2,329,327,842.90, a decline of 5.6%[16] - Total equity attributable to shareholders decreased by 5.77% to CNY 2,168,698,348.30 compared to the end of the previous year[5] Cash Flow - The company's cash flow from operating activities for the year-to-date was CNY 6,459,630.18, an increase of 123.94% compared to the same period last year[9] - Cash flow from operating activities generated a net cash inflow of 6,459,630.18 yuan, a significant improvement from a net outflow of -26,985,970.24 yuan in the same period last year[19] - Total cash inflow from operating activities was 938,271,738.73 yuan, down 17% from 1,129,765,120.22 yuan in the previous year[19] - Cash outflow from operating activities totaled 931,812,108.55 yuan, a decrease of 19% compared to 1,156,751,090.46 yuan in the previous year[19] - Cash flow from investing activities resulted in a net outflow of -32,561,751.58 yuan, an improvement from -45,641,577.81 yuan in the previous year[20] - Cash flow from financing activities showed a net outflow of -24,003,979.53 yuan, compared to -133,318,381.68 yuan in the same period last year[20] Current Assets - As of September 30, 2023, the company's total current assets amounted to CNY 1,678,036,453.32, a decrease from CNY 1,726,866,278.86 at the beginning of the year, representing a decline of approximately 2.8%[14] - The cash and cash equivalents decreased to CNY 286,653,283.75 from CNY 333,563,469.59, reflecting a reduction of about 14.1%[14] - Accounts receivable increased to CNY 1,060,482,340.14 from CNY 1,054,380,439.95, showing a slight increase of approximately 0.6%[14] - Inventory decreased to CNY 224,744,278.44 from CNY 230,948,244.32, indicating a decline of about 2.7%[14] - Non-current assets totaled CNY 1,158,110,607.63, down from CNY 1,182,709,449.01, representing a decrease of approximately 2.1%[14] Research and Development - The company reported a significant increase in development expenditures, which rose by 52.25% to CNY 39,439,164.66 due to increased R&D investments[9] - Research and development expenses for Q3 2023 were CNY 72,322,144.99, down from CNY 77,127,746.32 in Q3 2022, indicating a reduction of 6.5%[17] Shareholder Information - The company reported a total of 10 major shareholders, with the largest shareholder holding 12.41% of the shares[12] - The company has engaged in various financing activities, with significant pledges and frozen shares among major shareholders[12] Other Information - The report indicates no new product launches or significant technological advancements mentioned during the conference call[13] - The company did not report any net profit from the merged entity prior to the merger, with both periods showing 0.00 yuan[19] - The company has not yet audited the third-quarter report[21] - Other comprehensive income for Q3 2023 was CNY 17,661,732.83, compared to CNY 15,393,191.05 in Q3 2022, reflecting an increase of 14.8%[16] - Basic and diluted earnings per share for the third quarter were -0.3818, compared to -0.0458 in the previous period[19]